| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Feb―21 |
Cellular and molecular insights into the individual difference in COVID-19 mRNA vaccine responses |
Hiroki ISHIKAWA, Masato HIROTA, Miho TAMAI |
| 2 |
[GO] |
2022―Apr―26 |
Comparison of young and elderly COVID-19 cynomolgus macaque models reflecting human COVID-19 pathological conditions |
Emiko URANO, Tomotaka OKAMURA, Wataru KAMITANI, Yoshihiro KAWAOKA, Yasuhiro YASUTOMI |
| 3 |
[GO] |
2022―Apr―26 |
Infectivity-enhancing antibodies against SARS-CoV-2 |
Yafei LIU, Yukoh NAKAZAKI, Hisashi ARASE |
| 4 |
[GO] |
2021―Dec―23 |
Development of intranasal Sendai virus vector-based vaccine against COVID-19 |
Ryutaro SHIMAZAKI, Kohji KUSANO |
| 5 |
[GO] |
2021―Dec―23 |
Predictive serum markers for severe COVID-19 illness |
Masaya SUGIYAMA |
| 6 |
[GO] |
2021―Dec―23 |
Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials |
Marwa AKAO, Joohyeon WOO, Shingo IWAMI, Shoya IWANAMI |
| 7 |
[GO] |
2021―Dec―23 |
Development of an inactivated COVID-19 vaccine |
Kengo SONODA |
| 8 |
[GO] |
2021―Dec―23 |
Identification of G-quadruplex sequences in severe acute respiratory syndrome coronavirus 2 |
Shogo SASAKI, Junya KITAMURA, Hiroyuki ENDO, Akira SHIRAISHI, Kazunori IKEBUKURO, Tetsuya MIZUTANI, Masayuki TERA |
| 9 |
[GO] |
2021―Dec―23 |
Open collaborative framework providing severe acute respiratory syndrome coronavirus 2 infection cell culture assays for accelerating drug development |
Koichi WATASHI |
| 10 |
[GO] |
2021―Oct―15 |
Establishment of a nonhuman primate model for development of vaccines and anti-viral drugs against COVID-19 |
Yasushi ITOH |
| 11 |
[GO] |
2021―Oct―15 |
Development of an mRNA vaccine against COVID-19 |
Masayuki YABUTA, Fumihiko TAKESHITA, Shizuko UENO, Natsuki TANAKA, Takahiro YANO, Keiji OE, Chie NIKAIDO, Ken J. ISHII, Masaki IMAI, Yoshihiro KAWAOKA, Toru TANZAWA |
| 12 |
[GO] |
2021―Oct―15 |
Study protocol for a randomized, open-label, non-controlled Phase I/II Study to assess safety and immunogenicity of twice or three times dosing of intramuscular COVID-19 DNA vaccine in healthy adults |
Hironori NAKAGAMI, Hiroki HAYASHI, Tetsuya ISHIHAMA, Yuichi DAIKYOJI, Chieka SASAKURA, Tadashi MIKAMI, Takao KOMATSUNO, Yoshimi SAITO, Kazuo SUZUKI, Akihiko MURAKAMI, Naoya SATO, Ei YAMADA, Hiromi RAKUGI, Ryuichi MORISHITA |
| 13 |
[GO] |
2021―Sep―09 |
Ameliorative effect of anti-complement factor antibody on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected macaque |
Yasunori NIO |
| 14 |
[GO] |
2021―Aug―11 |
Toward control of severe acute respiratory syndrome coronavirus 2 disease (COVID-19) |
Masaki IMAI, Yoshihiro KAWAOKA |
| 15 |
[GO] |
2021―Aug―11 |
Remote review practices of Institutional Review Boards during the COVID-19 pandemic in Korea: comparison with a Japanese study |
Naoki TSUTSUMI, Chieko KURIHARA, Kotone MATSUYAMA, Kikuo TSUKAHARA, Tatsushi TSUDA, Kyoko IMAMURA |
